Advertisement

Everolimus

  • Jens Hasskarl
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 211)

Abstract

Everolimus (RAD001) is an oral protein kinase inhibitor of the mTOR (mammalian target of rapamycin) serine/threonine kinase signal transduction pathway. The mTOR pathway regulates cell growth, proliferation and survival, and is frequently deregulated in cancer.

The EMA has approved Everolimus as Afinitor®
  • for the treatment of hormone receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor,

  • for the treatment of unresectable or metastatic, well- or moderately differentiated neuroendocrine tumors of pancreatic origin in adults with progressive disease, and

  • for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors of gastrointestinal or lung origin in adults with progressive disease, and

  • for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy

And as Votubia®
  • for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC), who are at risk of complications (based on factors such as tumor size or presence of aneurysm, or presence of multiple or bilateral tumors) but who do not require immediate surgery, and

  • for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with TSC who require therapeutic intervention but are not amenable to surgery, and

  • as an add-on treatment in patients from 2 years of age with seizures related to TSC that have not responded to other treatments (https://www.novartis.com/news/media-releases/novartis-drug-votubiar-receives-eu-approval-treat-refractory-partial-onset).

The FDA has approved Everolimus as Afinitor®
  • for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after the failure of treatment with letrozole or anastrozole,

  • for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease,

  • for the treatment of adult patients with advanced RCC after failure of treatment with sunitinib or sorafenib,

  • for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.

  • for the treatment of adult and pediatric patients, 3 years of age or older, with SEGA associated with TSC who require therapeutic intervention but are not candidates for curative surgical resection.

Everolimus shows promising clinical activity in additional indications. Multiple Phase II and Phase III trials of everolimus alone or in combination and will help to further elucidate the role of mTOR in oncology. For a review on everolimus as immunosuppressant, please consult other sources.

Keywords

RAD001 mTOR Everolimus TSC Cancer NET 

References

  1. Andre F et al (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol: Official J Am Soc Clin Oncol 28(34):5110–5115CrossRefGoogle Scholar
  2. Andre F et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(6):580–591CrossRefPubMedGoogle Scholar
  3. Awada A et al (2008) The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 44(1):84–91CrossRefPubMedGoogle Scholar
  4. Barnes JA et al (2013) Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 98(4):615–619CrossRefPubMedPubMedCentralGoogle Scholar
  5. Baselga J et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol: Official J Am Soc Clin Oncol 27(16):2630–2637CrossRefGoogle Scholar
  6. Baselga J et al (2012a) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529CrossRefPubMedGoogle Scholar
  7. Baselga J et al (2012b) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England J Med 366(2):109–119CrossRefGoogle Scholar
  8. Bissler JJ et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869):817–824CrossRefPubMedGoogle Scholar
  9. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5):335–348CrossRefPubMedGoogle Scholar
  10. Boulay A et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res: Official J Am Assoc Cancer Res 11(14):5319–5328CrossRefGoogle Scholar
  11. Carracedo A et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3 K-dependent feedback loop in human cancer. J Clin Investig 118(9):3065–3074PubMedGoogle Scholar
  12. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91(8):1420–1424CrossRefPubMedPubMedCentralGoogle Scholar
  13. Crazzolara R et al (2009) Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113(14):3297–3306CrossRefPubMedGoogle Scholar
  14. Doi T et al (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol: Official J Am Soc Clin Oncol 28(11):1904–1910CrossRefGoogle Scholar
  15. Ehninger D et al (2008) Reversal of learning deficits in a Tsc2± mouse model of tuberous sclerosis. Nat Med 14(8):843–848CrossRefPubMedPubMedCentralGoogle Scholar
  16. Eng CP et al (1991) Inhibition of skin graft rejection in mice by rapamycin: a novel immunosuppressive macrolide. Transplant Proc 23(1 Pt 1):868–869PubMedGoogle Scholar
  17. Franz DN (2011) Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther 11(8):1181–1192CrossRefPubMedGoogle Scholar
  18. Franz DN (2013) Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics 7:211–221PubMedPubMedCentralGoogle Scholar
  19. Franz DN et al (2016) Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS ONE 11(6):e0158476CrossRefPubMedPubMedCentralGoogle Scholar
  20. French JA et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10056):2153–2163CrossRefPubMedGoogle Scholar
  21. Geoerger B et al (2001) Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61(4):1527–1532PubMedGoogle Scholar
  22. Hainsworth JD et al (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol: Official J Am Soc Clin Oncol 28(13):2131–2136CrossRefGoogle Scholar
  23. Haritunians T et al (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21(2):333–339CrossRefPubMedGoogle Scholar
  24. Hortobagyi GN et al (2016) Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 34(5):419–426CrossRefPubMedGoogle Scholar
  25. Houghton PJ (2010) Everolimus. Clin Cancer Res 16(5):1368–1372CrossRefPubMedPubMedCentralGoogle Scholar
  26. Hurvitz SA et al (2013) A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat 141(3):437–446CrossRefPubMedPubMedCentralGoogle Scholar
  27. Huynh H et al (2009) RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 13(7):1371–1380CrossRefPubMedGoogle Scholar
  28. Jacinto E et al (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11):1122–1128CrossRefPubMedGoogle Scholar
  29. Jerusalem G et al (2011) Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 125(2):447–455CrossRefPubMedGoogle Scholar
  30. Johnston PB et al (2010) A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 85(5):320–324PubMedPubMedCentralGoogle Scholar
  31. Knox JJ et al (2017) Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol 28(6):1339–1345CrossRefPubMedPubMedCentralGoogle Scholar
  32. Krueger DA et al (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New England J Med 363(19):1801–1811CrossRefGoogle Scholar
  33. Lane HA et al (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res: Official J Am Assoc Cancer Res 15(5):1612–1622CrossRefGoogle Scholar
  34. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293CrossRefPubMedPubMedCentralGoogle Scholar
  35. Levine AJ et al (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20(3):267–275CrossRefPubMedGoogle Scholar
  36. Lu CH et al (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res: Official J Am Assoc Cancer Res 13(19):5883–5888CrossRefGoogle Scholar
  37. Majumder PK et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10(6):594–601CrossRefPubMedGoogle Scholar
  38. Mak BC, Yeung RS (2004) The tuberous sclerosis complex genes in tumor development. Cancer Invest 22(4):588–603CrossRefPubMedGoogle Scholar
  39. Manning BD, Cantley LC (2003) United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 31(Pt 3):573–578PubMedGoogle Scholar
  40. Meikle L et al (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci: Official J Soc Neurosci 28(21):5422–5432CrossRefGoogle Scholar
  41. Mita M et al (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 17(12):1947–1954CrossRefPubMedGoogle Scholar
  42. Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456CrossRefPubMedGoogle Scholar
  43. Motzer RJ et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265CrossRefPubMedGoogle Scholar
  44. Motzer RJ et al (2016) Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol 27(3):441–448CrossRefPubMedGoogle Scholar
  45. Nagata Y et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117–127CrossRefPubMedGoogle Scholar
  46. Nakai Y et al (2017) Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. Oncol Rep 37(1):227–234CrossRefPubMedGoogle Scholar
  47. Nishioka C et al (2008) Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 22(12):2159–2168CrossRefPubMedGoogle Scholar
  48. O’Donnell A et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol: Official J Am Soc Clin Oncol 26(10):1588–1595CrossRefGoogle Scholar
  49. O’Reilly T, McSheehy PM (2010) Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 3(2):65–79CrossRefPubMedPubMedCentralGoogle Scholar
  50. O’Reilly T et al (2010) Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 65(4):625–639CrossRefPubMedGoogle Scholar
  51. Ohtsu A et al (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31(31):3935–3943CrossRefPubMedPubMedCentralGoogle Scholar
  52. Orlova KA, Crino PB (2010) The tuberous sclerosis complex. Ann N Y Acad Sci 1184:87–105CrossRefPubMedPubMedCentralGoogle Scholar
  53. Pavel ME et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005–2012CrossRefPubMedGoogle Scholar
  54. Pavel ME et al (2017a) Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol 28(7):1569–1575CrossRefPubMedGoogle Scholar
  55. Pavel ME et al (2017b) Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. Clin Pharmacol Ther 101(4):462–468CrossRefPubMedGoogle Scholar
  56. Podsypanina K et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten± mice. Proc Natl Acad Sci USA 98(18):10320–10325CrossRefPubMedGoogle Scholar
  57. Ravaud A et al (2015) RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alpha-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 26(7):1378–1384CrossRefPubMedGoogle Scholar
  58. Renner C et al (2012) A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 97(7):1085–1091CrossRefPubMedPubMedCentralGoogle Scholar
  59. Saunders P et al (2011) The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 96(1):69–77CrossRefPubMedGoogle Scholar
  60. Schuler W et al (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64(1):36–42CrossRefPubMedGoogle Scholar
  61. Sehgal SN (1995) Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 17(6):660–665CrossRefPubMedGoogle Scholar
  62. Singh J et al (2014) Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 16(2):R32CrossRefPubMedPubMedCentralGoogle Scholar
  63. Swain SM et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471CrossRefPubMedPubMedCentralGoogle Scholar
  64. Taguchi F et al (2011) Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs 29(6):1198–1205CrossRefPubMedGoogle Scholar
  65. Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. New England J Med 367(19):1783–1791CrossRefGoogle Scholar
  66. Villanueva A et al (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology, 2008. 135(6):1972–83, 1983 e1–11Google Scholar
  67. Wang M et al (2014) Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol 165(4):510–518CrossRefPubMedGoogle Scholar
  68. Wanner K et al (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134(5):475–484CrossRefPubMedGoogle Scholar
  69. Witzig TE et al (2016) PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 34(15_suppl):7506–7506Google Scholar
  70. Witzig TE et al (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25(2):341–347CrossRefPubMedGoogle Scholar
  71. Wong M (2012) mTOR as a potential treatment target for epilepsy. Future Neurol 7(5):537–545CrossRefPubMedPubMedCentralGoogle Scholar
  72. Xu ZZ et al (2013) Combination of Rituximab and the mTOR inhibitor Everolimus (RAD001) in Diffuse large B cell lymphoma. Leuk LymphomaGoogle Scholar
  73. Yao JC et al (2016) Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin OncolGoogle Scholar
  74. Yao JC et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol: Official J Am Soc Clin Oncol 26(26):4311–4318CrossRefGoogle Scholar
  75. Yao JC et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol: Official J Am Soc Clin Oncol 28(1):69–76CrossRefGoogle Scholar
  76. Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. New England J Med 364(6):514–523CrossRefGoogle Scholar
  77. Yao JC et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968–977CrossRefPubMedGoogle Scholar
  78. Yoon DH et al (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106(6):1039–1044CrossRefPubMedPubMedCentralGoogle Scholar
  79. Zhu AX et al (2011) Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117(122):5094–5102CrossRefPubMedPubMedCentralGoogle Scholar
  80. Zhu AX et al (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312(1):57–67CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Faculty of MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations